SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Saegis Pharmaceuticals
• Treatments: (3-aminopropyl)(n-butyl)phosphinic acid

Criteria

Inclusion Criteria:

• 55 to 90 years of age

• Diagnosed with mild to moderate Alzheimer's disease

• Willing caregiver

• In general good health

Exclusion Criteria:

• Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.

Prohibited Meds:

• Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)